SEER HOME
LIVE

Serial Number

79340655

Owner

Seer Medical Holdings Limited

Attorney

Charles G. Zug

Filing Date

Mar 11, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SEER HOME Trademark

Serial Number: 79340655 • Registration: 7601769

SEER HOME is a trademark filed by Seer Medical Holdings Limited on March 11, 2022. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Seer Medical Holdings Limited (10 trademarks)

Level 4, 700 Swanston Street

Entity Type: 81

Seer Medical Pty Ltd (10 trademarks)

c/- Lockwood Partners Pty Ltd,

Entity Type: 99

Trademark Details

Filing Date

March 11, 2022

Registration Date

December 17, 2024

Published for Opposition

October 8, 2024

Goods & Services

Software as a service (SAAS) services featuring software for medical purposes for diagnosis, monitoring, management and treatment of neurological conditions; software as a service (SAAS) services featuring software for health purposes for diagnosis, monitoring, management and treatment of neurological conditions; software as a service (SAAS) services featuring software for use in the medical treatment of epilepsy for monitoring and diagnosing neurological diseases, cardiac conditions, and sleep disorders; software as a service (SAAS) services featuring software, namely, providing online non-downloadable computer database programs for enabling the provision of diagnostic medical and health information for use in body monitoring including the management of epilepsy, heart and sleep disorders; software as a service (SAAS) services featuring software for the recording, collection, organisation, management and transmission of medical and health information for diagnostic body monitoring for the management of epilepsy, cardiac and sleep disorders; software as a service (SAAS) services featuring software for use with medical devices for diagnosis, monitoring, management and treatment of neurological conditions; software as a service (SAAS) services featuring software for use with medical diagnostic devices for diagnosis, monitoring, management and treatment of neurological conditions; software as a service (SAAS) services featuring software for use with health monitoring devices for diagnosis, monitoring, management and treatment of neurological conditions; software as a service (SAAS) services featuring software for use in the treatment of epilepsy for monitoring and diagnosing neurological diseases; software as a service (SAAS) services featuring software for use in the management of epilepsy for monitoring and diagnosing neurological diseases; none of the foregoing in relation to reagents, software or hardware for the analysis of proteins, proteomes, or biological data, and goods and services in the fields of biomolecules, metabolomics, lipidomics, genomics, epigenomics, proteomics, transcriptomics, and secretomics

Downloadable computer programs for medical purposes for diagnosis, monitoring, management and treatment of neurological conditions; downloadable computer programs for health purposes for diagnosis, monitoring, management and treatment of neurological conditions; downloadable computer application software for use in the provision of and access to medical treatment for neurological conditions; downloadable computer application software for the provision of medical and health information for use in body monitoring, namely, the management of epilepsy, heart and sleep disorders; downloadable computer application software for the recording, collection, organisation, management and transmission of medical and health information for diagnostic body monitoring relating to neurological and cardiac conditions and sleep disorders; downloadable software for use with medical devices for diagnosis, monitoring, management and treatment of neurological conditions; downloadable software for use with medical diagnostic devices for diagnosis, monitoring, management and treatment of neurological conditions; downloadable software for use with health monitoring devices for diagnosis, monitoring, management and treatment of neurological conditions; downloadable software for use in the treatment of epilepsy for monitoring and diagnosing neurological diseases; downloadable software for use in the management of epilepsy for monitoring and diagnosing neurological diseases; downloadable electronic publications in the nature of scientific and medical research journal articles in the field of medical treatment for epilepsy, cardiac, and sleep disorders and for providing information to patients and doctors in relation to epilepsy and other neurological and cardiac conditions and the diagnosis, monitoring, management and treatment thereof; downloadable computer database programs relating to diagnostic medical and health information for body monitoring for the management of epilepsy, heart and sleep disorders; none of the foregoing in relation to reagents, software or hardware for the analysis of proteins, proteomes, or biological data, and goods and services in the fields of biomolecules, metabolomics, lipidomics, genomics, epigenomics, proteomics, transcriptomics, and secretomics

Advisory services relating to medical problems; advisory services relating to medical services; health care consultancy services, namely, consulting services in the field of medical care; medical advisory services; medical analysis services relating to the treatment of patients; medical assistance; medical care services; medical counselling; medical testing and medical analysis services, all for diagnostic purposes; medical information retrieval services, namely medical information provided to medical professionals and patients from remote locations via the Internet and global computer networks through the use of archived medical images and a data storage and retrieval system; medical services; all of the foregoing in relation to the diagnosis, monitoring, management and treatment of epilepsy, neurological conditions, cardiac conditions, and sleep disorders; none of the foregoing in relation to reagents, software or hardware for the analysis of proteins, proteomes, or biological data, and goods and services in the fields of biomolecules, metabolomics, lipidomics, genomics, epigenomics, proteomics, transcriptomics, and secretomics

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 7, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 19, 2025 FINO
GENERIC MADRID TRANSACTION SENT TO IB
May 19, 2025 XXSS
GENERIC MADRID TRANSACTION CREATED
May 19, 2025 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 17, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 17, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 17, 2024 R.PR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Nov 21, 2024 ERRR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Oct 11, 2024 ADCH
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 8, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 8, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 18, 2024 NONP
EXPARTE APPEAL TERMINATED
Sep 3, 2024 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 3, 2024 CNSA
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Sep 3, 2024 AMPX
ASSIGNED TO EXAMINER
Aug 30, 2024 DOCK
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 26, 2024 PARI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Aug 20, 2024 JURT
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 12, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 25, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 25, 2023 OPNR
EX PARTE APPEAL-INSTITUTED
Sep 13, 2023 EXPI
EXPARTE APPEAL RECEIVED AT TTAB
Sep 13, 2023 EXAF
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 4, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 4, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 4, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 4, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 4, 2023 COAR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 13, 2023 GNFN
FINAL REFUSAL E-MAILED
Mar 13, 2023 GNFR
FINAL REFUSAL WRITTEN
Mar 13, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 4, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 3, 2023 TROA
REFUSAL PROCESSED BY IB
Aug 23, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 3, 2022 RFCS
REFUSAL PROCESSED BY MPU
Aug 3, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 15, 2022 RFCR
NON-FINAL ACTION WRITTEN
Jul 14, 2022 CNRT
ASSIGNED TO EXAMINER
Jul 13, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
May 24, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 20, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 19, 2022 REPR